Dec 14, 2010 12:08 PM by Bea Karnes
INDIANAPOLIS (AP) - Eli Lilly says it suspended a late-stage study of tasisulam as a potential skin cancer treatment because of safety concerns, but the company will continue studying the drug candidate in other cancer studies.
The company did not disclose the specific safety issues involved in the suspension. Researchers are analyzing the data in the study on metastatic melanoma patients. The condition is the most common form of skin cancer. Meanwhile, the company says it will continue to develop the drug as a potential treatment for breast, ovarian and other cancers, citing different dosing.
For up-to-date information on cancer treatments, contact the Dorcy Cancer Center in Pueblo.